PharVision Advisers’s Nu Skin NUS Stock Holding History

PharVision Advisers’s Portfolio NUS Stock Details NUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-81,429	Closed	-$561K	–	445
2024 Q4	$561K	Buy	+81,429	New	+$560K	0.47%	28

Other funds holding NUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

PharVision Advisers's NUS Position: Q1 2025 in Review

PharVision Advisers sold out of Nu Skin (NUS) in Q1 2025, closing a stake of 81,429 shares — an estimated $561K sold.

PharVision Advisers first reported a position in NUS in Q4 2024 and held it in 1 quarter. The position peaked at $561K in Q4 2024. 195 funds tracked by Wall St. Rank hold NUS as of Q1 2025.

PharVision Advisers reported no remaining Nu Skin position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 81,429 Nu Skin shares in Q1 2025, an estimated $561K.
PharVision Advisers first reported a position in Nu Skin in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Nu Skin position peaked at $561K in Q4 2024.
195 funds tracked by Wall St. Rank held Nu Skin as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.